NewAmsterdam Pharma (NAMS) EBT Margin (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted EBT Margin of 1593.45% for Q1 2026, up 99.32% sequentially from 234134.38% in Q4 2025, and down 26615.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) EBT Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported EBT Margin for 4 years, with the latest figure at 1593.45% in Q1 2026.
- Quarterly EBT Margin fell 26615.0% year-over-year to 1593.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 942.76% (down 54530.0% YoY) and the FY2025 annual result came in at 905.74%, down 37549.0% from the prior year.
- EBT Margin improved to 1593.45% in Q1 2026 per NAMS's latest filing, from 234134.38% in the prior quarter.
- Over five years, EBT Margin peaked at 57.19% in Q3 2024 and troughed at 234134.38% in Q4 2025.
- A 4-year average of 21346.18% and a median of 1602.62% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin surged 543869 bps in 2024, then sank 23341266 bps in 2025.
- Over 4 years, EBT Margin stood at 6160.4% in 2023, then jumped by 88 bps to 721.71% in 2024, then sank by 32342 bps to 234134.38% in 2025, then jumped by 99 bps to 1593.45% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 1593.45%, 234134.38%, and 20691.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | -1,732.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,732.91% |
| Mar 31, 2026 | -1,593.45% |
| Dec 31, 2025 | -234,134.38% |
| Sep 30, 2025 | -20,691.09% |
| Jun 30, 2025 | -90.70% |
| Mar 31, 2025 | -1,327.30% |
| Dec 31, 2024 | -721.71% |
| Sep 30, 2024 | -57.19% |
| Jun 30, 2024 | -1,711.58% |
| Mar 31, 2024 | -6,692.86% |
| Dec 31, 2023 | -6,160.40% |
| Sep 30, 2023 | -1,602.62% |
| Jun 30, 2023 | -2,230.11% |
| Mar 31, 2023 | -486.94% |